MW031

DRUG2 trials

Sponsors

Mabwell (Shanghai) Bioscience Co., Ltd.

Conditions

Osteoporosis, Postmenopausal

Phase 1

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults

CompletedNCT04798313

Mabwell (Shanghai) Bioscience Co., Ltd.Osteoporosis, Postmenopausal

Start: 2020-06-02End: 2020-12-31Updated: 2021-03-15

Phase 3

Efficacy and Safety of MW031 in PMO Subjects

CompletedNCT05215977

Mabwell (Shanghai) Bioscience Co., Ltd.Osteoporosis, Postmenopausal

Start: 2019-12-27End: 2021-09-27Updated: 2023-10-11

Related Papers

Randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of the denosumab biosimilar MW031 in Chinese postmenopausal women with osteoporosis

Expert Opinion on Biological Therapy2024-05-163 citations

Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled trial

Expert Opinion on Biological Therapy2023-03-097 citations